Advertisement

Topics

Clinical Trials About "Aequus Granted European Patent Once Weekly Transdermal Aripiprazole" RSS

22:07 EDT 19th October 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Aequus Granted European Patent Once Weekly Transdermal Aripiprazole" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Aequus Granted European Patent Once Weekly Transdermal Aripiprazole" on BioPortfolio

We have published hundreds of Aequus Granted European Patent Once Weekly Transdermal Aripiprazole news stories on BioPortfolio along with dozens of Aequus Granted European Patent Once Weekly Transdermal Aripiprazole Clinical Trials and PubMed Articles about Aequus Granted European Patent Once Weekly Transdermal Aripiprazole for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aequus Granted European Patent Once Weekly Transdermal Aripiprazole Companies in our database. You can also find out about relevant Aequus Granted European Patent Once Weekly Transdermal Aripiprazole Drugs and Medications on this site too.

Showing "Aequus Granted European Patent Once Weekly Transdermal Aripiprazole" Clinical Trials 1–25 of 3,500+

Extremely Relevant

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

The goal of the current trial is to determine efficacy and safety of Once-weekly aripiprazole in reducing Total Tic Severity in children and adolescents with Tourette's Disorder.


Relevant

Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials

The purpose of this study is to provide aripiprazole to schizophrenic outpatients and Community Treated Patients who are currently receiving aripiprazole therapy on another BMS sponsored clinical trial.

Aripiprazole in Fragile X Syndrome

The purpose of this study is to determine the effectiveness and tolerability of aripiprazole in the treatment of children and adolescents with FXS. We hypothesize that aripiprazole will be effective in decreasing aggression, SIB, agitation, and interfering repetitive behavior commonly observed in individuals with FXS. We also hypothesize that aripiprazole will be well tolerated.


Aripiprazole Oral Acceptability Trial

The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.

Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD

There is a scarcity of clinical trials assessing the effects of medications in children with bipolar disorder. This study aims to assess the efficacy of Aripiprazole associated with Methylphenidate (MPH)for the treatment of children and adolescents with bipolar disorder comorbid with ADHD who improve in maniac symptoms while receiving aripiprazole but did not have an adequate response in ADHD symptoms. The study design is a 4-week randomized, double blind, cross-over group tria...

Effect on Cognitive Function of a Treatment With Aripiprazole

To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.

Aripiprazole for Prevention of Relapse to Cocaine Use

This study will evaluate whether, compared to placebo, aripiprazole increases the time to relapse to cocaine use in abstinent polydrug users in methadone maintenance therapy. Based on a the results of studies with aripiprazole in a preclinical model of relapse, we hypothesize that aripiprazole will reduce relapse to cocaine use.

Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents

The purpose of this study is to determine whether moderately ill Asian schizophrenic patients can be switched from their previous antipsychotic medication to aripiprazole with minimal adverse clinical consequences, and elucidate both pharmacokinetic and pharmacodynamic factors associated with clinical efficacy of aripiprazole.

Aripiprazole in Children and Adolescents With Bipolar I Disorder

The purpose of this trial is to test the safety and efficacy of two doses of aripiprazole in child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features.

Aripiprazole in Adolescents With Schizophrenia

The purpose of this trial is to test the safety and efficacy of aripiprazole in adolescent patients with schizophrenia for a period of at least 6 weeks.

Aripiprazole in Children With Autism: A Pilot Study

This is a 6-week open pilot study of aripiprazole for the treatment of adolescents, aged 12 to 18 years, diagnosed with autism. Children who qualify for the study will be treated with aripiprazole for 6 weeks. Treatment is provided at no cost.

An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder

This is an investigator-initiated study whose primary aim is to determine the effectiveness of aripiprazole (Abilify®) in helping persons with symptoms of mania whose current medications do not completely control those symptoms. Aripiprazole is a medication that has been approved by the United States Food and Drug Administration (FDA) for the treatment of Schizophrenia. A secondary aim of this research is to explore whether CYP 2D6 polymorphisms are related to side eff...

A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy

The purpose of this study is to determine whether a reduced dose of aripiprazole is effective in treating patients with major depressive disorder

Aripiprazole Open-Label Rollover Study

The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia.

A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices

The purpose of this clinical research study is to evaluate the overall effectiveness of 8 week of aripiprazole treatment.

Broad Effectiveness: Study With Aripiprazole

The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

This study will provide long-term safety data for patients who are taking aripiprazole for up to 1 year. Most patients enrolled in this study will have participated in a short-term study with aripiprazole (CN138-178 [NCT00332241] or CN138-179 [NCT00337571]).

Efficacy and Safety of Aripiprazole

This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.

Combination Treatment for Augmenting Language in Children With ASD

The study will consist of two main elements: the enrollment of 72 children aged 6-11 years with ASD and low language competency to receive a thrice-weekly one hour language intervention for 12 weeks; and, beginning at the same time, subjects will be equally randomized to receive either aripiprazole (Abilify) (flexibly dosed from 2-10 mg per day) or placebo for 12 weeks.

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia

Aripiprazole Effects on Alcohol Reactivity and Consumption

The purpose of this study is to determine whether aripiprazole (marketed dopamine stabilizer) is effective in reducing of alcohol craving compared to placebo.

Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole

This proposal aims to use well-validated methodologies such as dual energy x-ray absorptiometry (DEXA), frequently sampled oral glucose tolerance tests (fsOGTTs), and hyperinsulinemic euglycemic clamps to characterize the metabolic effects of 12 weeks of aripiprazole treatment following chronic pretreatment with olanzapine, quetiapine, risperidone or ziprasidone. We hypothesize that switching to aripiprazole treatment will induce improvements in total body adiposity, inf...

Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism

The purpose of this study is to evaluate the safety and effectiveness of aripiprazole in patients with autism in the real world clinical setting in Japan.

Aripiprazole Treatment of the Prodrome

The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewer side effects. This study will explore how well Aripiprazole treats symptoms of early-onset psychotic disorders as well as symptoms that may indicate risk for such disorders, including unusual thoughts, suspiciousness, perceptual abnormalities, social isolation, and sudden chang...

A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence

The purpose of this study is to gather systematic clinical data on whether aripiprazole, a partial dopamine agonist, beneficially affects schizophrenia plus cocaine dependence subjects. Since aripiprazole has established effects against schizophrenia, the study focuses on whether aripiprazole concurrently reduces co-morbid cocaine dependence in schizophrenia plus cocaine dependence sufferers compared to a standard typical antipsychotic treatment (perphenazine). The working hyp...


More From BioPortfolio on "Aequus Granted European Patent Once Weekly Transdermal Aripiprazole"

Advertisement
Quick Search
Advertisement
Advertisement